Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Crispr Therapeutics AG's current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles, making future pipeline progress critical. Management is focused on improving ...
Researchers in Basel have created SEED/Harvest, a new CRISPR-based technique that tags proteins without leaving any genetic “scars.” By blending two powerful methods, it allows scientists to study ...
Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results